Elevation Oncology Inc (NASDAQ:ELEV) shares, rose in value on Wednesday, April 16, with the stock price up by 5.49% to the previous day’s close as strong demand from buyers drove the stock to $0.33.
Actively observing the price movement in the last trading, the stock closed the session at $0.31, falling within a range of $0.3025 and $0.3411. The value of beta (5-year monthly) was 1.668. Referring to stock’s 52-week performance, its high was $4.53, and the low was $0.22. On the whole, ELEV has fluctuated by -31.32% over the past month.
With the market capitalization of Elevation Oncology Inc currently standing at about $19.59 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-05.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ELEV’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ELEV currently trading nearly 21.62% and -26.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.74, while the 7-day volatility ratio is showing 11.49% which for the 30-day chart, stands at 11.91%. Furthermore, Elevation Oncology Inc (ELEV)’s beta value is 1.56, and its average true range (ATR) is 0.04.
A comparison of Elevation Oncology Inc (ELEV) with its peers suggests the former has fared considerably weaker in the market. ELEV showed an intraday change of 5.49% in last session, and over the past year, it shrunk by -92.53%%.
Data on historical trading for Elevation Oncology Inc (NASDAQ:ELEV) indicates that the trading volumes over the past 10 days have averaged 1.14 and over the past 3 months, they’ve averaged 1.60 million. According to company’s latest data on outstanding shares, there are 59.13 million shares outstanding.
Nearly 12.09% of Elevation Oncology Inc’s shares belong to company insiders and institutional investors own 65.79% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.16 million shares as on 2025-03-31, resulting in a short ratio of 4.02. According to the data, the short interest in Elevation Oncology Inc (ELEV) stood at 1455.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 8.56 million. The stock has fallen by -41.22% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ELEV stock heading into the next quarter.
